Has Muhammad Haq, MD received payments from drug or device companies?

Yes. Drug and device makers reported $30,984 in general payments to Muhammad Haq, MD across 160 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Muhammad Haq, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Muhammad Haq, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Muhammad Haq, MD

Cardiovascular Disease · Jersey City, NJNPI 1750724811

Payments from drug & device makers

What this record shows

This record is dominated by grants: $20,040 of the $30,984 with a category attached, or 64.7%. 22 manufacturers reported payments, led by Boston Scientific at 34.3% of the total. Reporting peaked in 2021 at $14,465 and has fallen 93.4% since, to $948 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,984in general payments, 2019–2025

Across 160 payments — averaging $193.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$11K
Medtronic$9K
Abbott$5K
Biotronik Inc.$3K
Philips North America LLC$1K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$463
plus $2K from 16 others

What the payments were for

Consulting fees$1500%
Grants$20,04065%
Travel & lodging$4,36114%
Food & beverage$5,52318%
Education$9103%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	21	$10,622
Medtronic	17	$8,832
Abbott	36	$4,867
Biotronik Inc.	24	$3,147
Philips North America LLC	9	$1,437
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	22	$463
Edwards Lifesciences	2	$357
Boehringer Ingelheim	2	$243
Medical Device Business Services, Inc.	1	$183
Biosense Webster, Inc.	3	$167
Novartis	10	$164
Impulse Dynamics (USA) Inc.	1	$135
E.r. Squibb & Sons, L.L.C.	1	$134
Baxter Healthcare	1	$50
Bridgebio Pharma, Inc.	2	$38
Teva Pharmaceuticals USA, Inc.	2	$30
Amgen	1	$29
Elutia, Inc.	1	$20
Bayer	1	$18
Neurocrine Biosciences, Inc.	1	$18
Cardiva Medical, Inc.	1	$16
Neurelis, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,984 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey →

Medicare billing

Part B allowed, 2024

$164,765

Medicare patients

582

Services billed

1,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	46	$41,534
Metoprolol Succinate	23	$280
Atorvastatin Calcium	20	$188
Amiodarone Hcl	19	$169
Metoprolol Tartrate	33	$154
ClopidogrelClopidogrel Bisulfate	19	$150
Losartan Potassium	16	$105
Furosemide	23	$94
Carvedilol	14	$77
Spironolactone	17	$54
Lisinopril	12	$19

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Jersey City

Joven DungoJersey City$104K
Marc CohenNewark$762K
Peter FarrugiaColts Neck$600K
Felix Dailey-SterlingGuttenberg$568K
Ramzan ZakirNew Brunswick$342K
Richard KovachBrowns Mills$300K
Andrea RussoCamden$293K
John KostisNew Brunswick$225K
Dilip ViswanathHaddon Heights$167K
David PowellSpringfield$162K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →